Icatibant Stada

Icatibant, the active ingredient in Icatibant Stada, is a bradykinin B2 receptor antagonist presented as a 30 mg/1 mL solution for injection for subcutaneous use. It treats hereditary angioedema (C1 inhibitor deficiency) in patients experiencing acute attacks.

GNH USA supplies Icatibant Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is used to manage acute attacks of hereditary angioedema, a disorder driven by excessive bradykinin activity.

- Hereditary angioedema (C1 inhibitor deficiency): reduces swelling during acute attacks. - Hereditary angioedema type I: provides rapid relief of edema. - Hereditary angioedema type II: provides rapid relief of edema.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin redness. - Swelling at injection site: transient edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure. - Angioedema unrelated to HAE: unexpected swelling of face, lips, or airway. - Thrombocytopenia: low platelet count observed in rare cases. - Necrotic injection site: tissue damage at injection site. - Severe hypersensitivity: rash, fever, or organ involvement.

Before using Icatibant, consider the following safety measures.

- Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown safety; weigh benefits against possible infant exposure. - Renal impairment: no specific dosage adjustment, but monitor renal function. - Concomitant ACE inhibitors: may increase risk of bradykinin‑mediated angioedema; assess need for co‑administration. - Hypersensitivity: do not use in patients with known allergy to icatibant or any excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence bradykinin pathways or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may potentiate bradykinin‑mediated angioedema; avoid concurrent use. - Angiotensin receptor blockers: increased risk of angioedema; avoid co‑administration. - Prophylactic C1‑inhibitor concentrate: simultaneous use may confound clinical assessment; avoid.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate edema; monitor for worsening symptoms. - Estrogen‑containing contraceptives: can increase frequency of HAE attacks; observe closely. - Diuretics: may affect fluid balance; watch for hypotension or electrolyte shifts.